CCS1477

First-in-class p300/CBP inhibitor for prostate and other cancers

  • 80,000+

    Men with prostate cancer

    could ultimately benefit from CCS1477 annually

  • 20,000+

    Patients with blood cancers

    multiple myeloma, AML, lymphomas

  • 50+

    Epigenetic-related targets

    investigated over time by the CellCentric team

  • 1

    Drug prioritised, advanced

    CCS1477 in the clinic, for multiple indications

The science

CCS1477, a first-in-class small molecule drug to treat prostate and other cancers

There is a large and growing population of prostate cancer patients that are resistant to second generation anti-hormonal drugs (Xtandi, Zytiga, Erleada). CCS1477 addresses this through targeting the key drivers of resistance and late stage disease; the androgen receptor (AR), AR splice variants (AR-SV) and c-Myc.

Other cancer tumours are also susceptible to p300/CBP inhibition, notably specific haematological cancers; multiple myeloma, acute myeloid leukaemia (AML) and certain lymphomas.

Backed by strong pre-clinical data, CCS1477 is now being trialed in patients.

The team

A core team with deep experience of drug discovery and development

The company is supported by a strong network of clinical, scientific and commercial advisors. CellCentric also actively collaborates with a number of world-leading cancer research centres on the effects of CCS1477 and p300/CBP inhibition.

Latest tweets by @cellcentric

Follow us

Interesting to see the new paper by Liu et al. on p300/CBP inhibition, PD-L1, and the treatment of cancer: nature.com/articles/s4138… pic.twitter.com/ERyrtLUQ6u

Regular virtual core team meetings now up and running (some IT glitches still to address..). Productive working from home. pic.twitter.com/1K1FPGXdoJ

Many thanks to our amazing sites, CROs & consultants supporting patients who remain on our clinical trials in this challenging time. pic.twitter.com/yjQQmitQcO